Olivier Morand (Azafaros)

Dutch biotech scores €25M in small mol­e­cule bet to tack­le lyso­so­mal stor­age dis­or­ders

While a host of biotech com­pa­nies work on gene and en­zyme re­place­ment ther­a­pies for cer­tain lyso­so­mal stor­age dis­or­ders, a Dutch play­er is aim­ing to slot in its small mol­e­cule ap­proach across a range of these rare in­her­it­ed meta­bol­ic dis­or­ders.

The com­pa­ny — Aza­faros — found­ed in 2018 based on sci­ence de­vel­oped from Lei­den Uni­ver­si­ty and Am­s­ter­dam Uni­ver­si­ty Med­ical Cen­ter has se­cured €25 mil­lion in Se­ries A fi­nanc­ing as it works on shep­herd­ing its lead ex­per­i­men­tal drug in­to the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.